Premium
Thio‐TEPA and supervoltage radiotherapy for carcinoma of the ovary
Author(s) -
Deutsch Melvin,
Parsons John A.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197204)29:4<1038::aid-cncr2820290452>3.0.co;2-y
Subject(s) - medicine , radiation therapy , ovary , stage (stratigraphy) , carcinoma , surgery , oncology , paleontology , biology
One hundred and twenty‐one cases of carcinoma of the ovary treated post‐operatively with irradiation are evaluated. Eighty‐seven also received at least one course of TSPA, approximately 0.8 mg/kg IV or 1.2 mg/kg IP over 3 days, which was usually given prior to radiotherapy. Thirty‐four additional patients are considered who were referred for radiotherapy only after recurrent or persistent disease. TSPA did not appear to provide additional benefit when given before postoperative radiotherapy in Stage I and Stage II cases. The value of TSPA in more advanced stages is uncertain. Radiotherapy, with or without TSPA, given after the appearance of recurrent disease had very little effect in the majority of patients. Rupture of a cyst with spillage at operation had no detectable effect on prognosis. Suggestions are made for possible improvements in the management of ovarian carcinoma.